Compare Alcon AG (ALC) vs W W Grainger Inc (GWW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs W W Grainger Inc — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while W W Grainger Inc trades at $1,350.14 (market cap $64.04B). The key difference: W W Grainger Inc is the larger of the two by market cap, and W W Grainger Inc pays the higher dividend (0.68%). Which is the better fit depends on your goals.
| ALC | GWW | |
|---|---|---|
Market Cap | $32.69B | $64.04B |
Sector | Health | Technology |
52-Week High | $92.22 | $1.37K |
52-Week Low | $62.02 | $918.18 |
Enterprise Value | $36.28B | $66.13B |
Dividend Yield | 0.54% | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
GWW trades at $1,370.16, up 2.02% today, showing strong momentum with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $11.65, beating estimates by 14%, and raised full-year guidance. Revenue growth remains solid at 10.1% year-over-year, with operating margins expanding 110 basis points to 16.7%. Recent news highlights Grainger's 25-year partnership with the American Red Cross and multiple analyst upgrades citing momentum potential.
The outlook remains positive with analyst consensus target of $1,260 suggesting modest upside. Strong profitability metrics (48.1% ROE, 19.66% ROA) support valuation, though elevated P/E of 36.84 warrants monitoring. Key risks include industrial sector cyclicality and margin pressure from rising costs. Institutional sentiment leans cautious with 63% hold ratings despite recent earnings beat.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
